PhaseBio Pharmaceuticals EV/Operating CF

EV/Operating CF of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Operating CF growth rates and interactive chart. A valuation metric that measures the enterprise value of a company compared to its operating cash flow. Operating cash flow (OCF) is the amount of cash generated by a company's normal business operations. It can be different from reported net income due to accrual accounting, that is expenses and revenues are recognized differently than cash is received. The cash going in and out of the business is what ultimately determines its financial health, so it's one of the most important metrics to watch. A low EV/OCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/OCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/Operating CF of PhaseBio Pharmaceuticals is -1.41 (as of December 30, 2020)
  • EV/Operating CF for the quarter ending September 29, 2021 was -2.65 (a 2.62% increase compared to previous quarter)
  • Year-over-year quarterly EV/Operating CF decreased by -3.33%
  • Annual EV/Operating CF for 2020 was -1.41 (a -48.47% decrease from previous year)
  • Annual EV/Operating CF for 2019 was -2.74 (a -237.51% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Operating CF of PhaseBio Pharmaceuticals

Most recent EV/Operating CFof PHAS including historical data for past 10 years.

Interactive Chart of EV/Operating CF of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals EV/Operating CF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -2.65 -2.59
2020 -0.92 -1.41
2019 -2.74 -1.41 -10.49 -11.17 -2.74
2018 2.0 1.03 2.0

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.